Elise Arrivé1, François Dabis. 1. INSERM 593, Institute for Public Health, Epidemiology and Development (ISPED), Victor Segalen University, Bordeaux, France.
Abstract
PURPOSE OF REVIEW: With the large international mobilization against HIV/AIDS, more HIV-infected people in resource-limited settings have access to antiretroviral therapy, including pregnant women. The relevance of simplified prophylactic antiretroviral regimens for the prevention of mother-to-child transmission of HIV may become questionable due to their lower efficacy and their higher risk of inducing viral resistance than fully suppressive antiretroviral therapy. RECENT FINDINGS: Field implementation of current recommendations, impact of prophylactic regimens on subsequent antiretroviral therapy response and possible new indications of antiretroviral therapy in pregnant women will be reviewed in this paper. SUMMARY: Prophylactic antiretroviral prevention of mother-to-child transmission regimens reached only 10% of the HIV-infected pregnant women in 2006, who were usually offered single-dose nevirapine only. The operational links between antenatal care and antiretroviral therapy programmes can now be documented and demonstrate good results in terms of safety and efficacy. The negative impact of single-dose nevirapine exposure on subsequent first-line antiretroviral therapy appears worse for mothers with advanced HIV disease at the time of delivery and short interval before antiretroviral therapy initiation. Strengthening the links between antenatal care and antiretroviral therapy programmes is critical for antiretroviral therapy-eligible HIV-infected pregnant women in terms of prevention of mother-to-child transmission and subsequent antiretroviral therapy response. The breastfeeding period could be a new indication for antiretroviral therapy in this population.
PURPOSE OF REVIEW: With the large international mobilization against HIV/AIDS, more HIV-infected people in resource-limited settings have access to antiretroviral therapy, including pregnant women. The relevance of simplified prophylactic antiretroviral regimens for the prevention of mother-to-child transmission of HIV may become questionable due to their lower efficacy and their higher risk of inducing viral resistance than fully suppressive antiretroviral therapy. RECENT FINDINGS: Field implementation of current recommendations, impact of prophylactic regimens on subsequent antiretroviral therapy response and possible new indications of antiretroviral therapy in pregnant women will be reviewed in this paper. SUMMARY: Prophylactic antiretroviral prevention of mother-to-child transmission regimens reached only 10% of the HIV-infected pregnant women in 2006, who were usually offered single-dose nevirapine only. The operational links between antenatal care and antiretroviral therapy programmes can now be documented and demonstrate good results in terms of safety and efficacy. The negative impact of single-dose nevirapine exposure on subsequent first-line antiretroviral therapy appears worse for mothers with advanced HIV disease at the time of delivery and short interval before antiretroviral therapy initiation. Strengthening the links between antenatal care and antiretroviral therapy programmes is critical for antiretroviral therapy-eligible HIV-infected pregnant women in terms of prevention of mother-to-child transmission and subsequent antiretroviral therapy response. The breastfeeding period could be a new indication for antiretroviral therapy in this population.
Authors: Karin van der Merwe; Matthew F Chersich; Karl Technau; Yvonne Umurungi; Francesca Conradie; Ashraf Coovadia Journal: J Acquir Immune Defic Syndr Date: 2006-12-15 Impact factor: 3.731
Authors: Neil A Martinson; Didier K Ekouevi; Francois Dabis; Lynn Morris; Pumla Lupodwana; Besigin Tonwe-Gold; Puleng Dhlamini; Renaud Becquet; Jan G Steyn; Valériane Leroy; Ida Viho; Glenda E Gray; James A McIntyre Journal: J Acquir Immune Defic Syndr Date: 2007-06-01 Impact factor: 3.731
Authors: Ibou Thior; Shahin Lockman; Laura M Smeaton; Roger L Shapiro; Carolyn Wester; S Jody Heymann; Peter B Gilbert; Lisa Stevens; Trevor Peter; Soyeon Kim; Erik van Widenfelt; Claire Moffat; Patrick Ndase; Peter Arimi; Poloko Kebaabetswe; Patson Mazonde; Joseph Makhema; Kenneth McIntosh; Vladimir Novitsky; Tun-Hou Lee; Richard Marlink; Stephen Lagakos; Max Essex Journal: JAMA Date: 2006-08-16 Impact factor: 56.272
Authors: Debra J Jackson; Mickey Chopra; Tanya M Doherty; Mark Se Colvin; Jonathan B Levin; Juana F Willumsen; Ameena E Goga; Pravi Moodley Journal: AIDS Date: 2007-02-19 Impact factor: 4.177
Authors: Taha E Taha; Donald R Hoover; Newton I Kumwenda; Susan A Fiscus; George Kafulafula; Chiwawa Nkhoma; Shu Chen; Estelle Piwowar; Robin L Broadhead; J Brooks Jackson; Paolo G Miotti Journal: J Infect Dis Date: 2007-05-24 Impact factor: 5.226
Authors: Wendy Mphatswe; Natasha Blanckenberg; Gareth Tudor-Williams; Andrew Prendergast; Christina Thobakgale; Nompumelelo Mkhwanazi; Noel McCarthy; Bruce D Walker; Photini Kiepiela; Philip Goulder Journal: AIDS Date: 2007-06-19 Impact factor: 4.177
Authors: Fulvia Milena Cribiù; Roberta Erra; Lorenza Pugni; Carlota Rubio-Perez; Lidia Alonso; Sara Simonetti; Giorgio Alberto Croci; Garazi Serna; Andrea Ronchi; Carlo Pietrasanta; Giovanna Lunghi; Anna Maria Fagnani; Maria Piñana; Matthias Matter; Alexandar Tzankov; Luigi Terracciano; Andres Anton; Enrico Ferrazzi; Stefano Ferrero; Enrico Iurlaro; Joan Seoane; Paolo Nuciforo Journal: J Clin Invest Date: 2021-03-15 Impact factor: 14.808
Authors: Ingrid Cardenas; Robert E Means; Paulomi Aldo; Kaori Koga; Sabine M Lang; Carmen J Booth; Carmen Booth; Alejandro Manzur; Enrique Oyarzun; Roberto Romero; Gil Mor Journal: J Immunol Date: 2010-06-16 Impact factor: 5.422